BRIMBLECOMBE ROGER W 4
4 · VERTEX PHARMACEUTICALS INC / MA · Filed Mar 16, 2010
Insider Transaction Report
Form 4
BRIMBLECOMBE ROGER W
Director
Transactions
- Exercise/Conversion
Common Stock
2010-03-15$38.44/sh+10,000$384,400→ 10,000 total - Sale
Common Stock
2010-03-15$43.10/sh−10,000$431,000→ 0 total - Exercise/Conversion
Stock Option
2010-03-15−10,000→ 0 totalExercise: $38.44From: 2000-06-01Exp: 2010-05-31→ Common Stock (10,000 underlying)
Footnotes (4)
- [F1]Transaction made pursuant to Dr. Brimblecombe's company approved sales plan established under Rule 10b5-1.
- [F2]Open market sales reported on this line occurred at a weighted average price of $43.10 (range $42.80 to $43.52).
- [F3]Dr. Brimblecombe undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- [F4]Right to buy under under 1996 Stock and Option Plan, fully vested on grant date, 6/1/2000.